Publication of a paper in Nature Biomedical Engineering highlights improved delivery and efficacy of therapeutics using Evox Therapeutics’ targeted exosomes
Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.
This article is featured on another website.
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
Revolutionizing the Canavan Disease Treatment Market
Canavan disease, a rare and fatal neurological disorder caused by a mutation in the ASPA gene, leads to a deficiency in the enzyme aspartoacylase.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance … Read more
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
Marcy l’Étoile, France – June 16th, 2025 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance … Read more